Skip to main content
SpringerLink
Log in

Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kastritis E et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385(1):46–58

    Article  CAS  Google Scholar 

  2. Tai YT et al (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123(20):3128–3138

    Article  CAS  Google Scholar 

  3. Trudel S et al (2019) Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J 9(4):37

    Article  Google Scholar 

  4. Palladini G et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541–4549

    Article  CAS  Google Scholar 

  5. Cornell RF et al (2018) Subsequent treatment outcomes of multiple myeloma refractory to CD38-monoclonal antibody therapy. Blood 132:2015

    Article  Google Scholar 

Download references

Acknowledgements

We thank the clinical research coordinators who contributed to this study and the funding that supports continued research in amyloidosis. For their continued support at Tufts in the Davis Program, we thank the donors who support the Amyloidosis and Myeloma Research Fund at Tufts, the Sidewater Family Fund, the Amyloidosis Foundation, David and Barbara Levine (in memoriam), and the Demarest Lloyd Jr Foundation.

Author information

Authors and Affiliations

  1. The John Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, 800 Washington Street, Box 826, Boston, MA, 92111, USA

    Yifei Zhang, Denis Toskic, Hashim Mann & Raymond Comenzo

  2. Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, 800 Washington Street, Box 826, Boston, MA, 92111, USA

    Yifei Zhang, Stacey Pan, Hashim Mann & Raymond Comenzo

  3. Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA

    Amandeep Godara & Douglas Sborov

  4. University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ankit Kansagra

Authors
  1. Yifei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amandeep Godara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stacey Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Denis Toskic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hashim Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Douglas Sborov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raymond Comenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ankit Kansagra
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, investigation, writing: Zhang Y. Conceptualization, supervision, writing: Comenzo RL, Kansagra A. Acquisition of data: Zhang Y, Godara A, Mann H, Sborov D, Pan S, Toskic D, Kansagra A, Comenzo RL.

Corresponding author

Correspondence to Yifei Zhang.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Godara, A., Pan, S. et al. Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. Ann Hematol 101, 2119–2121 (2022). https://doi.org/10.1007/s00277-022-04890-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04890-z

Search

Navigation